Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type … Read more
Corcept Therapeutics Incorporated (CORT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.059x
Based on the latest financial reports, Corcept Therapeutics Incorporated (CORT) has a cash flow conversion efficiency ratio of 0.059x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($38.45 Million) by net assets ($647.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Corcept Therapeutics Incorporated - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Corcept Therapeutics Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Corcept Therapeutics Incorporated Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Corcept Therapeutics Incorporated ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gruma SAB de CV
OTCGREY:GPAGF
|
0.082x |
|
H B Fuller Company
NYSE:FUL
|
0.053x |
|
Community Bank System Inc
NYSE:CBU
|
0.042x |
|
Nisshin Seifun Group Inc
F:NFR
|
N/A |
|
INDIVIOR PLC DL 050
F:2IVB
|
N/A |
|
Oil India Limited
NSE:OIL
|
0.054x |
|
Demant A/S
PINK:WILLF
|
0.238x |
|
PotlatchDeltic Corp
NASDAQ:PCH
|
0.034x |
Annual Cash Flow Conversion Efficiency for Corcept Therapeutics Incorporated (2003–2025)
The table below shows the annual cash flow conversion efficiency of Corcept Therapeutics Incorporated from 2003 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $647.80 Million | $142.00 Million | 0.219x | -24.79% |
| 2024-12-31 | $679.59 Million | $198.07 Million | 0.291x | +16.25% |
| 2023-12-31 | $506.70 Million | $127.04 Million | 0.251x | +4.57% |
| 2022-12-31 | $501.84 Million | $120.32 Million | 0.240x | -46.33% |
| 2021-12-31 | $375.81 Million | $167.89 Million | 0.447x | +53.85% |
| 2020-12-31 | $523.34 Million | $151.97 Million | 0.290x | -20.81% |
| 2019-12-31 | $371.18 Million | $136.12 Million | 0.367x | -12.53% |
| 2018-12-31 | $275.88 Million | $115.67 Million | 0.419x | +31.39% |
| 2017-12-31 | $190.97 Million | $60.94 Million | 0.319x | -28.21% |
| 2016-12-31 | $41.38 Million | $18.39 Million | 0.444x | +162.67% |
| 2015-12-31 | $18.50 Million | $3.13 Million | 0.169x | -97.91% |
| 2014-12-31 | $-3.39 Million | $-27.38 Million | 8.080x | +558.26% |
| 2013-12-31 | $21.02 Million | $-37.06 Million | -1.763x | -202.41% |
| 2012-12-31 | $61.78 Million | $-36.02 Million | -0.583x | +25.93% |
| 2011-12-31 | $34.81 Million | $-27.40 Million | -0.787x | +24.96% |
| 2010-12-31 | $21.24 Million | $-22.29 Million | -1.049x | -28.98% |
| 2009-12-31 | $22.09 Million | $-17.97 Million | -0.813x | +25.11% |
| 2008-12-31 | $16.91 Million | $-18.36 Million | -1.086x | -45.95% |
| 2007-12-31 | $14.73 Million | $-10.96 Million | -0.744x | +79.63% |
| 2006-12-31 | $6.36 Million | $-23.24 Million | -3.654x | -463.80% |
| 2005-12-31 | $26.59 Million | $-17.23 Million | -0.648x | -117.07% |
| 2004-12-31 | $45.95 Million | $-13.72 Million | -0.299x | +69.43% |
| 2003-12-31 | $10.24 Million | $-10.00 Million | -0.977x | -- |